Advancing novel mitochondrial therapies for FA cardiomyopathy: a pragmatic collaboration to move new therapies forward
|Dec 20 2022
Measuring ataxia in children with Friedreich ataxia
|Dec 20 2022
Imaging of glutathione and GABA in the brain as biomarkers of Friedreich Ataxia
|Dec 19 2022
TGFβ signaling activity as disease biomarkers and therapeutic targets in Friedreich’s Ataxia
|Dec 19 2022
Evaluation of ARMMs-mediated delivery of Cas9 protein complexed with gRNAs as a non-viral disease-modifying strategy for Friedreich’s Ataxia
|Oct 19 2022
Illuminating how SynGRs liberate gene expression from heterochromatin
|Oct 19 2022
Engineering adeno-associated viral vectors to evade immune responses
|Sep 20 2022
Functional electrical stimulation (FES) cycling training to improve motor and cardiac functions in patients with Friedreich’s Ataxia: a feasibility and efficacy study
|Sep 19 2022
Calcium communication among intracellular compartments in FA patient-derived cells
|Aug 20 2022
Detection and enhancement of tissue NAD+ levels in Friedreich’s Ataxia
|Jun 20 2022
A New Ultrasensitive Single-Molecule Assay for Frataxin Measurement
|Jun 19 2022
Rescue of Friedreich’s Ataxia cells by DNA methylation editing of the FXN gene